182 related articles for article (PubMed ID: 36098485)
1. Developing HDAC4-Selective Protein Degraders To Investigate the Role of HDAC4 in Huntington's Disease Pathology.
Macabuag N; Esmieu W; Breccia P; Jarvis R; Blackaby W; Lazari O; Urbonas L; Eznarriaga M; Williams R; Strijbosch A; Van de Bospoort R; Matthews K; Clissold C; Ladduwahetty T; Vater H; Heaphy P; Stafford DG; Wang HJ; Mangette JE; McAllister G; Beaumont V; Vogt TF; Wilkinson HA; Doherty EM; Dominguez C
J Med Chem; 2022 Sep; 65(18):12445-12459. PubMed ID: 36098485
[TBL] [Abstract][Full Text] [Related]
2. Hdac4 Interactions in Huntington's Disease Viewed Through the Prism of Multiomics.
Federspiel JD; Greco TM; Lum KK; Cristea IM
Mol Cell Proteomics; 2019 Aug; 18(8 suppl 1):S92-S113. PubMed ID: 31040226
[TBL] [Abstract][Full Text] [Related]
3. HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration.
Mielcarek M; Landles C; Weiss A; Bradaia A; Seredenina T; Inuabasi L; Osborne GF; Wadel K; Touller C; Butler R; Robertson J; Franklin SA; Smith DL; Park L; Marks PA; Wanker EE; Olson EN; Luthi-Carter R; van der Putten H; Beaumont V; Bates GP
PLoS Biol; 2013 Nov; 11(11):e1001717. PubMed ID: 24302884
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.
Jia H; Pallos J; Jacques V; Lau A; Tang B; Cooper A; Syed A; Purcell J; Chen Y; Sharma S; Sangrey GR; Darnell SB; Plasterer H; Sadri-Vakili G; Gottesfeld JM; Thompson LM; Rusche JR; Marsh JL; Thomas EA
Neurobiol Dis; 2012 May; 46(2):351-61. PubMed ID: 22590724
[TBL] [Abstract][Full Text] [Related]
5. Blocking the association of HDAC4 with MAP1S accelerates autophagy clearance of mutant Huntingtin.
Yue F; Li W; Zou J; Chen Q; Xu G; Huang H; Xu Z; Zhang S; Gallinari P; Wang F; McKeehan WL; Liu L
Aging (Albany NY); 2015 Oct; 7(10):839-53. PubMed ID: 26540094
[TBL] [Abstract][Full Text] [Related]
6. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
Cho IK; Yang B; Forest C; Qian L; Chan AWS
PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
[TBL] [Abstract][Full Text] [Related]
7. Frequency of nuclear mutant huntingtin inclusion formation in neurons and glia is cell-type-specific.
Jansen AH; van Hal M; Op den Kelder IC; Meier RT; de Ruiter AA; Schut MH; Smith DL; Grit C; Brouwer N; Kamphuis W; Boddeke HW; den Dunnen WF; van Roon WM; Bates GP; Hol EM; Reits EA
Glia; 2017 Jan; 65(1):50-61. PubMed ID: 27615381
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase knockouts modify transcription, CAG instability and nuclear pathology in Huntington disease mice.
Kovalenko M; Erdin S; Andrew MA; St Claire J; Shaughnessey M; Hubert L; Neto JL; Stortchevoi A; Fass DM; Mouro Pinto R; Haggarty SJ; Wilson JH; Talkowski ME; Wheeler VC
Elife; 2020 Sep; 9():. PubMed ID: 32990597
[TBL] [Abstract][Full Text] [Related]
9. The ubiquitin conjugating enzyme Ube2W regulates solubility of the Huntington's disease protein, huntingtin.
Wang B; Zeng L; Merillat SA; Fischer S; Ochaba J; Thompson LM; Barmada SJ; Scaglione KM; Paulson HL
Neurobiol Dis; 2018 Jan; 109(Pt A):127-136. PubMed ID: 28986324
[TBL] [Abstract][Full Text] [Related]
10. Bioinformatics analysis of Ras homologue enriched in the striatum, a potential target for Huntington's disease therapy.
Carbo M; Brandi V; Pascarella G; Staid DS; Colotti G; Polticelli F; Ilari A; Morea V
Int J Mol Med; 2019 Dec; 44(6):2223-2233. PubMed ID: 31638189
[TBL] [Abstract][Full Text] [Related]
11. Bim contributes to the progression of Huntington's disease-associated phenotypes.
Roberts SL; Evans T; Yang Y; Fu Y; Button RW; Sipthorpe RJ; Cowan K; Valionyte E; Anichtchik O; Li H; Lu B; Luo S
Hum Mol Genet; 2020 Jan; 29(2):216-227. PubMed ID: 31813995
[TBL] [Abstract][Full Text] [Related]
12. A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington's disease.
Chen KP; Hua KF; Tsai FT; Lin TY; Cheng CY; Yang DI; Hsu HT; Ju TC
J Neuroinflammation; 2022 Feb; 19(1):56. PubMed ID: 35219323
[TBL] [Abstract][Full Text] [Related]
13. Atypical ubiquitination by E3 ligase WWP1 inhibits the proteasome-mediated degradation of mutant huntingtin.
Lin L; Jin Z; Tan H; Xu Q; Peng T; Li H
Brain Res; 2016 Jul; 1643():103-12. PubMed ID: 27107943
[TBL] [Abstract][Full Text] [Related]
14. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease.
Wang N; Gray M; Lu XH; Cantle JP; Holley SM; Greiner E; Gu X; Shirasaki D; Cepeda C; Li Y; Dong H; Levine MS; Yang XW
Nat Med; 2014 May; 20(5):536-41. PubMed ID: 24784230
[TBL] [Abstract][Full Text] [Related]
15. Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease.
Zhou X; Li G; Kaplan A; Gaschler MM; Zhang X; Hou Z; Jiang M; Zott R; Cremers S; Stockwell BR; Duan W
Hum Mol Genet; 2018 May; 27(9):1545-1555. PubMed ID: 29462355
[TBL] [Abstract][Full Text] [Related]
16. Neuronal and astrocytic contributions to Huntington's disease dissected with zinc finger protein transcriptional repressors.
Gangwani MR; Soto JS; Jami-Alahmadi Y; Tiwari S; Kawaguchi R; Wohlschlegel JA; Khakh BS
Cell Rep; 2023 Jan; 42(1):111953. PubMed ID: 36640336
[TBL] [Abstract][Full Text] [Related]
17. A selective inhibitor of histone deacetylase 3 prevents cognitive deficits and suppresses striatal CAG repeat expansions in Huntington's disease mice.
Suelves N; Kirkham-McCarthy L; Lahue RS; Ginés S
Sci Rep; 2017 Jul; 7(1):6082. PubMed ID: 28729730
[TBL] [Abstract][Full Text] [Related]
18. Phenotype onset in Huntington's disease knock-in mice is correlated with the incomplete splicing of the mutant huntingtin gene.
Franich NR; Hickey MA; Zhu C; Osborne GF; Ali N; Chu T; Bove NH; Lemesre V; Lerner RP; Zeitlin SO; Howland D; Neueder A; Landles C; Bates GP; Chesselet MF
J Neurosci Res; 2019 Dec; 97(12):1590-1605. PubMed ID: 31282030
[TBL] [Abstract][Full Text] [Related]
19. Site-specific ubiquitination of pathogenic huntingtin attenuates its deleterious effects.
Hakim-Eshed V; Boulos A; Cohen-Rosenzweig C; Yu-Taeger L; Ziv T; Kwon YT; Riess O; Phuc Nguyen HH; Ziv NE; Ciechanover A
Proc Natl Acad Sci U S A; 2020 Aug; 117(31):18661-18669. PubMed ID: 32675242
[TBL] [Abstract][Full Text] [Related]
20. Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington's disease.
Luis-Ravelo D; Estévez-Silva H; Barroso-Chinea P; Afonso-Oramas D; Salas-Hernández J; Rodríguez-Núñez J; Acevedo-Arozena A; Marcellino D; González-Hernández T
Exp Neurol; 2018 Jan; 299(Pt A):137-147. PubMed ID: 29056363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
